An interventional study of Empowered Relief Course (Zoom) in Chronic Pain Due to Cancer and Pain Catastrophizing, sponsored by University of Oklahoma. Recruiting at 1 site in United States. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by University of Oklahoma · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,283 studies in Chronic Pain with a site in United States — 257 open to participants now, 348 under way, 7 of them phase 3. Chronic Pain · United States.
Among the 1,283 studies in Chronic Pain with a site in United States, this one is the 189th largest by planned enrollment of the 1,092 interventional ones that give a count, is one of 12 that started in 2027, is one of 803 with no phase, reaches primary completion later than 325 of the 347 other live ones, and was the 1,240th registered.
3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →257 of the 1,283 studies in Chronic Pain with a site in United States are open now. Recruiting first, the newest first:
Virginia Polytechnic Institute and State University · Sites in United States
Ages 18–65
Stanford University · Sites in United States
Ages 18+ · Women only
University of Massachusetts, Boston · Sites in United States
Ages 65+
Stanford University · Sites in United States
Ages 18+
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 14–26
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 120 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,283 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 81 · Phase 2 112 · Phase 3 72 · Phase 4 50
First in 1992; this study’s year is marked. 12 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 215 is above the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 60 across the 1,092 interventional studies, 100 across the 189 observational. Of the 848 that completed or were terminated, 386 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
209 of 1,283 have an industry lead sponsor. The 10 most frequent:
University of Oklahoma is the lead sponsor of 432 studies on the registry; 98 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 16 (38%) have results posted.
University of Oklahoma has 3 studies filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
139 of the studies in Chronic Pain with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05703178Phase 3Northwestern UniversityWeb-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia | 2026-11-30 |
| NCT06091202Phase 3Oregon Health and Science UniversityTele-Collaborative Outreach to Rural Patients With Chronic Pain | 2027-05-01 |
| NCT05459402Phase 3University of Maryland, BaltimoreDivided or Single Exposure (DOSE) Study | 2027-06-01 |
| NCT02979574Memorial Sloan Kettering Cancer CenterPEACE: Comparing Chronic Pain Treatment Options | 2026-11 |
| NCT03984565Staci Gruber, Ph.D.PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product | 2026-11 |
Add all 139 to your calendar (.ics) → With an account.
Among the 1,283 studies in Chronic Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled study to examine the efficacy of ER class in cancer survivors with chronic pain. Eligible participants will be randomly assigned to a ER class or a waitlist control condition. We will recruit 250 participants with a goal of having 200 completers (20% attrition). Participants in the control condition will be invited to attend ER class after the 3-month observation period.
The Empowered Relief (ER) study is a Zoom-based, 1-session, 2-hour, skills-based pain management class delivered by certified instructors. Participants learn three core pain relief skills, develop a personalized plan, and receive access to a free binaural audio app for daily use and supportive daily text messages. Participants will fill out a series of follow-up surveys at the 1, 2, and 3-month post-class mark. These surveys will be directly compared to surveys given to participants that do not complete the course. Class admittance will be randomized, however, participants not in the treatment group will have the option to take the course after the 3-month observatory period. ER has demonstrated moderate efficacy in individuals with chronic non-cancer pain, reducing pain intensity, pain interference, pain-related distress (pain catastrophizing), sleep disturbance, and anxiety. Because of its brief, didactic nature and delivery via Zoom, ER can accommodate large class sizes and may address access disparities among underserved cancer survivors. ER is currently being studied across various non-cancer populations and has been adopted as standard of care in leading healthcare institutions in the U.S. and abroad. Yet, Empowered Relief has not been tested in cancer survivors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
History of cancer diagnosis, completion of active cancer treatment, cancer free at the time of enrollment, experience of body pain most or every day, pain duration at least 3 months, and English fluency.
Exclusion Criteria:
Significant psychological and cognitive impairment that limits one's ability to complete study tasks (completion of online survey, attending the zoom-based ER class). Life-threatening acute illness (e.g., infection, heart attack, injury), and no access to a computer, a smartphone or a tablet.
Participants in this arm of the study will complete the one-time 2hr Empowered Relief zoom course. They will also complete a post-course survey as well as the standardized 1, 2, and 3-month follow-up surveys.
Behavioral: Empowered Relief Course (Zoom)
Participants in the Wait-List Control (WLC) arm will not have initial access to the empowered relief course. Additionally they will not have to complete a post-course survey. The WLC group will be asked to complete the 1, 2, and 3-month follow-up studies after no intervention. After this 3-month observatory period, WLC participants will have voluntary access to the Empowered Relief course.
This is a one-time 2 hour long skills-based pain management class delivered by certified instructors. Participants learn three core pain relief skills, develop a personalized plan, and receive access to a free binaural audio app for daily use and supportive daily text messages.
Overall treatment satisfaction
0-10 scale, higher scores indicate greater satisfaction, mean should be 8 or higher
Time frame: Immediately after intervention
Pain Intensity
0-10 scale, higher scores indicate higher pain
Time frame: 1 month after intervention
Pain Interference
T-scores, higher scores indicate higher pain interference
Time frame: 1 month after intervention
Pain Intensity
0-10 Scale, higher scores indicate higher pain
Time frame: 3 months after intervention
Pain Interference
T-scores, higher scores indicate higher pain interference
Time frame: 3 months after intervention
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Start is estimated for Jan 2027; primary completion for Dec 2029, 35 months later.
Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 35 months is above that.
Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.
Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jan 2027, on Nov 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.